Product Pipeline

Through the lens of hepatalin*, SciMar has conceived of four products designed to enhance human health. Each product is at a different stage of development.

NuPa Daily
Nupa Test

SciMar NuPa Test is a diagnostic test meal designed to measure hepatalin production. The test will help warn of the onset of prediabetes and type 2 diabetes years earlier than the oral glucose tolerance test, the current standard for diagnosing type 2 diabetes. A SciMar NuPa Test prototype is going into Phase 2 clinical trials (Canada).
Patents: U.S., Canada, Australia, U.K., Germany, France

Nupa Test
NuPa Daily

SciMar NuPa Daily is a nutraceutical antioxidant product designed to boost metabolism, strengthen immunity, improve mood balance, and protect the liver’s production of hepatalin*. SciMar NuPa Daily is available for purchase online in the U.S. A Canadian launch is planned for 2022; a launch in China is envisioned for 2023.
Patent: U.S.

NuPa Renew
NuPa Renew

SciMar NuPa Renew is SciMar’s pharmaceutical formulation which, when taken before a meal, will stimulate the healthy production of hepatalin and promote balanced nutrient partitioning. SciMar is preparing SciMar NuPa Renew for Phase 2B clinical trials.
Patents: U.S., Canada, China, Australia, U.K., Germany, France, Japan, New Zealand, Hong Kong

Hiss
Hiss

Hepatalin-S is the synthetic version of hepatalin. It is envisioned that the synthetic hormone will be used on its own or in combination with insulin for the long-term treatment of type 2 diabetes.
Patents: U.S., Canada, Australia, U.K., Germany, France

*In the academic literature prior to 2021, and in SciMar’s earlier materials, hepatalin was known as hepatic insulin-sensitizing substance (the “HISS” hormone).